FIGO 2009 IIIB期子宫内膜癌的实践模式与生存分析
基于美国国家癌症数据库2012-2016年手术分期的7363例III期子宫内膜癌患者,其中IIIB期478例(6%)。IIIB期患者接受化疗的比例在III期各亚期中最低,单纯放疗比例最高;调整预后因素后,IIIA期和IIIC1期患者的死亡风险显著高于IIIB期,而IIIC2期与IIIB期生存无显著差异。IIIB期患者中接受化疗联合放疗者总生存最佳。
要点
- IIIB期占III期子宫内膜癌的6%,术后49%接受化疗+放疗,28%单纯化疗,9%单纯放疗,14%未接受术后治疗。
- IIIB期患者接受化疗的比例在III期各亚期中最低,单纯放疗比例最高。
- 调整预后因素后,IIIA期(HR=0.64)和IIIC1期(HR=0.79)死亡风险显著高于IIIB期,IIIC2期与IIIB期无显著差异。
核心结论
- IIIB期子宫内膜癌的生存与腹主动脉旁淋巴结转移(IIIC2期)相似,且劣于其他III期亚期。
- IIIB期患者化疗使用较少、术后单纯放疗比例较高,实践模式与其他III期患者不同。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2012-2016年手术分期的III期子宫内膜癌患者,排除接受术前治疗者,最终纳入7363例。
主要发现
- IIIB期478例(6%),IIIA期1732例(23%),IIIC1期3457例(48%),IIIC2期1696例(23%)。
- IIIB期术后治疗:化疗+放疗49%,单纯化疗28%,单纯放疗9%,未治疗14%。
- IIIB期接受化疗的比例在III期各亚期中最低,单纯放疗比例最高。
- 调整预后因素后,IIIA期死亡风险比(HR)为0.64,IIIC1期为0.79,均显著高于IIIB期;IIIC2期与IIIB期生存无显著差异。
- IIIB期患者中接受化疗+放疗者总生存最佳。
关键数值与推荐
- IIIB期占III期子宫内膜癌的6%。
- IIIB期术后化疗+放疗占49%,单纯化疗28%,单纯放疗9%,未治疗14%。
- IIIA期死亡HR=0.64,IIIC1期HR=0.79(以IIIB期为参照)。
临床怎么用
- IIIB期子宫内膜癌术后可考虑化疗联合放疗,该方案与最佳总生存相关。
- 应关注IIIB期患者化疗使用不足、单纯放疗比例较高的实践差异。
局限性
- 回顾性数据库研究,可能存在选择偏倚和未测量混杂因素。
- 仅纳入手术分期患者,排除术前治疗者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the practice patterns and outcomes of patients with stage 3B endometrial cancer. METHODS: We queried the National Cancer Database for all surgically staged, stage 3 patients between 2012 and 2016. Patients who received any pre-operative therapy were excluded. Demographics, tumor factors, and adjuvant therapy for the stage 3 substages were compared. Logistic regression was used to identify factors associated with adjuvant therapy. Kaplan Meier curves were generated and compared using the log-rank test. Multivariable Cox Proportional Hazards Model was used to adjust for prognostic factors. Findings with p < 0.05 were considered significant. RESULTS: Of 7363 patients with stage 3 disease, 478 (6%) had stage 3B; 1732 (23%) had stage 3A, 3457 (48%) had stage 3C1, and 1696 (23%) had stage 3C2 disease. Post-surgical treatment consisted of: combined chemotherapy (CT) and radiation (RT) (49%), CT alone (28%), RT alone (9%), 14% received no postoperative therapy. Among all stage 3 substages, patients with stage 3B disease were the least likely to receive any CT, and the most likely to receive RT alone. After adjusting for known prognostic factors, patients with stage 3A (Hazard ratio (HR) of death = 0.64) and 3C1 (HR of death = 0.79) disease had significantly worse overall survival compared to stage 3B; survival was not demonstrably different from patients with stage 3C2 disease. Patients with stage 3B disease who received CT + RT had the best overall survival. CONCLUSION: Survival of patients with stage 3B disease is similar to that of patients with para-aortic node metastases and is inferior to all others with stage 3 endometrial cancer. Less frequent CT and a higher rate of post-operative RT alone, describes a distinct practice from that seen in other stage 3 patients.
引用
- Jou J, Charo L, Hom-Tedla M, et al. Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer. Gynecol Oncol. 2021. PMID: 34561099. doi:10.1016/j.ygyno.2021.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。